Working… Menu

SUTENT (SUNITINIB, SU11248)in Patients With Recurrent or Progressive Glioblastoma Multiforme (SURGE01-07)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00535379
Recruitment Status : Unknown
Verified January 2009 by Medical University Innsbruck.
Recruitment status was:  Active, not recruiting
First Posted : September 26, 2007
Last Update Posted : August 30, 2010
Information provided by:
Medical University Innsbruck

Brief Summary:

Clinical Part:

The objective of this study is to determine the efficacy and safety of SUTENT in patients with recurrent or progressive glioblastoma multiforme.Patients with tissue based diagnosis of intracranial glioblastoma multiforme, above 18 years of age and of both genders, who have a first tumor recurrence or progress after surgery, radiation- and chemotherapy will be included. The hypothesis is that SUTENT will significantly increase the progression free survival rate at 6 months in the study population.

Condition or disease Intervention/treatment Phase
Glioblastoma Multiforme Drug: Sunitinib Phase 2

Show Show detailed description

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 70 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: SUTENT (SUNITINIB, SU11248)in Patients With Recurrent or Progressive Glioblastoma Multiforme An Academic Prospective Single-arm Phase II Clinical Trial Including Ranslational Research Studies
Study Start Date : October 2007
Estimated Primary Completion Date : December 2010
Estimated Study Completion Date : January 2011

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: 1 Drug: Sunitinib
Patients will receive SUTENT 37.5mg (3 x 12.5mg capsules) PO daily in the morning after breakfast. After 2 weeks without treatment-related adverse events grade ≥ 2 (ECOG common toxicity criteria: refer to Protocol Attachment A.4) a SUTENT dose escalation to 50mg (4 x 12.5mg capsules) PO daily has to be performed. Treatment will continue until patients develop progression of disease or until unacceptable adverse events occur.
Other Name: SUTENT

Primary Outcome Measures :
  1. Progression-free survival rate at 6 months [ Time Frame: 6 months after tumor progression ]
  2. Median time to tumor progression [ Time Frame: Time to tumor progression ]

Secondary Outcome Measures :
  1. Overall survival [ Time Frame: Time from study inclusion to death ]
  2. Overall survival rate at 12 months [ Time Frame: 12 months after tumor progression ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients present with a first recurrence or first progression of a histological confirmed primary supratentorial glioblastoma multiforme WHO Grade IV (Classification following WHO criteria).
  • Patients with surgical resection of first tumor progression: Following standard therapy patients must have evidence of first tumor progression. In general, patients may have undergone prior surgical resection of the first tumor progression and will be eligible if the following conditions apply:
  • Patients must have recovered from the effects of surgery
  • To adequately asses the GBM before surgery and the extent of residual disease postoperatively, two MRIs scans have to be performed:
  • The first MRI scan within 2 weeks before surgery to document a progressed or recurrent GBM. The second MRI scan within 48 hours after surgery.
  • Patients without surgical resection of first tumor progression:
  • Patients must have evidence of first tumor progression following standard therapy as measured by a baseline MRI within 2 weeks prior to study enrollment (Macdonald criteria: i.e. tumor growth > 25% or new lesion).
  • Resolution of all acute toxic effects of prior therapy to grade ≤ 1 (except alopecia)
  • Patients must have an ECOG performance status of 0-2
  • Patients must be ≥ 18 years and ≤ 75 years of age, with a life expectancy of greater than 8 weeks
  • Patients must have adequate organ function as defined by the following criteria:

Bone Marrow Reserve - Platelets ≥ 75.000/μL

  • Absolute Neutrophil Count (ANC) ≥ 1500/μL
  • Hemoglobin ≥ 10.0 g/dL Blood Coagulation - aPTT ≤ 1.5 times upper limit of normal (ULN) Hepatic Function - ASAT and ALAT ≤ 1.5 times ULN
  • ALP ≤ 2.5 times ULN
  • Total Serum Bilirubin < 1 times ULN Renal Function - Serum Creatinine ≤ 1.5 times ULN Metabolism - Serum Albumin ≥ 3.0 g/dL Heart Function - Left Ventricular Ejection Fraction (LVEF) ≥ 50% as measured by transthoracic echocardiogram ECHO) All tests must be performed ≤ 3 days prior to study enrollment. Eligibility for hemoglobin count may be reached by transfusion
  • Signed and dated informed consent document by the patient, indicating that the patient has been informed of all the pertinent aspects of the trial prior to study enrollment
  • Willingness and ability of the patient to comply with scheduled visits, treatment plans, laboratory tests, and other study procedures

Exclusion Criteria:

  • The patient is active participant in another clinical trial.
  • Exclusion of patients in the event of

    • surgery for recurrence/progression within 1 week prior to study enrollment
    • chemotherapy within 4 weeks prior to study enrollment
    • treatment with more than one chemotherapy regime
    • radiation therapy within 8 weeks to study enrollment
    • evidence in baseline MRI of intratumoral or peritumoral hemorrhage deemed clinically significant by the treating physician (area of hemorrhage > 25% of tumor area)
  • Significant Co-Morbidities within 12 months prior to study enrollment

    • myocardial infarction, severe/unstable angina pectoris, coronary/peripheral artery bypass graft, congestive heart failure
    • pulmonary embolus
    • cerebro-vascular accident including TIA (transient ischemic attack)
  • Significant Co-Morbidities at Baseline Evaluation

    • Clinically significant ongoing cardiac dysrhythmias of grade ≥ 2, atrial fibrillation of any grade, QTc interval > 470 ms measured by electrocardiogram (ECG)
    • Hypertension that cannot be controlled by medications (>150/100 mmHg despite optimal medical therapy)
    • A known HIV (human immunodeficiency virus) or Hepatitis B/C infection or severe acute infection
  • Anticoagulation: Current treatment with therapeutic doses of Marcoumar / Sintrom excluding thrombosis prophylaxis with low dose Heparin.
  • Antiepileptic Drugs: Concurrent use of EIADs within 2 weeks of study enrollment (patients must discontinue EIAD treatment ≥ 14 days prior to study enrollment)
  • Pregnancy, Breastfeeding and Non-Contraception

    • Female patients who are pregnant or nursing
    • Patients who are sexually active and unwilling or unable to use a medically acceptable method of contraception during the trial.
  • Evidence of increased intracranial pressure

    • midline shift > 5 mm
    • distinct nausea and vomiting
  • Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that would impart excess risk associated with study participation or study drug administration, or which would make the patient inappropriate for entry into this study. The decision to enroll the patient in this study is in the judgment of the investigator.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00535379

Layout table for location information
LKH Feldkirch
Feldkirch, Austria
Medical University Innsbruck
Innsbruck, Austria, 6020
LNK Wagner-Jauregg
Linz, Austria
Paracelsus Medical University
Salzburg, Austria, 5020
Medical University Vienna
Vienna, Austria
Kaiser-Franz-Josef Spital Wien
Wien, Austria
University Hospital of Heidelberg
Heidelberg, Baden-Württemberg, Germany, 69120
University Hospital of Mannheim
Mannheim, Baden-Württemberg, Germany, 68167
University Hospital of Bonn
Bonn, Nordrhein-Westfalen, Germany, 53105
University Hospital of Berlin
Berlin, Germany, 13353
Sponsors and Collaborators
Medical University Innsbruck
Layout table for investigator information
Principal Investigator: Guenther Stockhammer, MD, Prof. Medical University Innsbruck
Additional Information:
Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Medical University Innsbruck, Department of Neurology Identifier: NCT00535379    
Other Study ID Numbers: EUDRACT-Nr. 2007-002142-37
First Posted: September 26, 2007    Key Record Dates
Last Update Posted: August 30, 2010
Last Verified: January 2009
Keywords provided by Medical University Innsbruck:
glioblastoma multiforme
Additional relevant MeSH terms:
Layout table for MeSH terms
Neoplasms, Neuroepithelial
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms, Glandular and Epithelial
Neoplasms, Nerve Tissue
Antineoplastic Agents
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Growth Substances
Physiological Effects of Drugs
Growth Inhibitors
Protein Kinase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action